Targeting Histamine Receptor 4 in CholinergicUrticaria with Izuforant (LEO 152020): Results from a Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Crossover trial. Cholinergicurticaria (CholU) is a common subtype of chronic inducible urticaria, where signs and symptoms (eg, pruritic wheals and angioedema) are triggered by sweating due to physical exercise, passive warming
CholinergicUrticaria: Subtype Classification and Clinical Approach. Cholinergicurticaria (CholU) is a subtype of chronic inducible urticaria with a chief complaint of itching and/or stinging, painful papular wheals that develop simultaneously with sweating. This review specifically focuses on several subtypes of CholU and specifically investigates the relationship between CholU and anhidrosis
Efficacy and Safety of Omalizumab (Xolair) for CholinergicUrticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial. Cholinergicurticaria (UCOL) is a highly disabling inducible urticaria triggered by an increase in core body temperature. To explore the safety and efficacy of omalizumab in controlling
Development and Validation of the CholinergicUrticaria Quality of Life Questionnaire: CholU-QoL. Cholinergicurticaria (CholU), a common form of chronic inducible urticaria, is characterized by itchy weals that occur in response to physical exercise or passive warming. CholU patients frequently exhibit a high burden of disease. As of yet, no specific instrument is available to assess their disease-related quality-of-life (QoL) impairment. The aim of this study was to develop and validate the first disease-specific QoL instrument for CholU patients, the CholinergicUrticaria Quality-of-Life Questionnaire (CholU-QoL). Using a combined approach of the literature search, semistructured patient interviews and expert opinion, we developed 96 potential CholU-QoL items. Subsequent item selection
Cholinergicurticaria patients of different age groups have distinct features. Cholinergicurticaria (CholU) is a common skin disease characterized by the development of pinpoint-sized weals and severe itch upon physical exercise. Little is known about the epidemiology of CholU. CholU can occur at any age and has the highest prevalence among young adults. As of now, it is unclear whether
Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With CholinergicUrticariaCholinergicUrticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals
Atopic predisposition in cholinergicurticaria patients and its implications. Cholinergicurticaria (CholU) is a frequent chronic urticaria disorder with itchy weal and flare-type skin reactions in response to physical exercise or passive warming. A higher frequency of atopy among CholU patients has been reported, but the significance of this observation is unclear. To assess the prevalence and comorbidity profiles as compared to non-atopic CholU patients. Atopic predisposition and cholinergicurticaria appear to be linked more closely than previously thought, which suggests shared pathogenetic mechanisms. Atopic patients with cholinergicurticaria have more severe disease and poorer quality of life than those who do not. Thus, all cholinergicurticaria patients should be assessed for atopic
Cholinergicurticaria: More than a simple inducible urticaria. Cholinergicurticaria (ChU) is characterized by small wheals induced by an elevated core temperature. Its pathomechanism and various aspects of its clinical manifestations are still poorly understood. This study aimed to evaluate the spectrum of symptoms and signs of ChU in Korean patients. We retrospectively reviewed the medical
Pure Cold-Induced CholinergicUrticaria in a Pediatric Patient Cold urticaria and cholinergicurticaria are two distinct entities. The presentation of exclusive cold-induced cholinergicurticaria is very rare. The patient described herein had experienced urticaria in the exclusive setting of exercising in a cold environment. Urticarial testing including laboratory and in-office testing was all negative. The patient has prevented urticaria symptoms with oral antihistamine therapy. Pure cold-induced cholinergicurticaria is rarely described in literature. This form of urticaria has yet to be described in a pediatric patient.
The significance of hypersensitivity to autologous sweat and serum in cholinergicurticaria: cholinergicurticaria may have different subtypes. The pathogenesis of cholinergicurticaria (ChU) has been unclear except for the involvement of acetylcholine. Attempts to classify ChU according to etiology have rarely been performed. To evaluate the significance of responsiveness to autologous sweat
Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergicurticaria. Cholinergicurticaria (CholU) is a common condition in which active or passive warming leads to development of pinpoint wheals, flares and itch. To develop a standardized protocol for diagnosing CholU and measuring trigger thresholds, independent of patients' fitness levels. Ten
Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With CholinergicUrticaria Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with cholinergicurticaria This is a phase 2a, randomised, double-blind, placebo-controlled, cross-over trial conducted in Germany at 3-6 sites. Subjects will be randomised to one of two treatment sequences (A and B
Cholinergicurticaria and exercise-induced anaphylaxis. In this article, we will present the physical manifestations of two similar conditions. The first is cholinergicurticaria. This is chronic urticaria precipitated by an elevated body temperature. The second is exercise-induced anaphylaxis. Anaphylaxis can be idiopathic, a result of a specific allergenic trigger (food, medication, or insect
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or CholinergicUrticaria This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or CholinergicUrticaria. This study is an open label Phase 1 study evaluating the safety , pharmacokinetics, and pharmacodynamics of a single dose of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or CholinergicUrticaria who remain symptomatic despite treatment with antihistamines. Twenty patients with Cold Contact Urticaria, ten patients with Symptomatic Dermographism, and ten patients with CholinergicUrticaria will be enrolled in four separate cohorts for a total
dermatographism, vibratory angio-oedema, aquagenic urticaria, cholinergicurticaria, and contact urticaria.Urticaria complicated by angio-oedemaSome people have urticaria that is complicated by angio-oedema, a swelling of the deeper dermis and tissues (e.g., mucosal surfaces), with laryngeal oedema potentially causing respiratory distress and death.[3] Angio-oedema is commonly associated with urticaria
Evaluation of different combined regimens in the treatment of cholinergicurticaria. : Cholinergicurticaria is uncommon and accounts for 10% of all young adults. To date, there is no effective therapy for cholinergicurticaria. : To determine the therapeutic efficacy of different drug combinations in the treatment of cholinergicurticaria. : The participants included in the study are in the age range of 16 to 29 years, with cholinergicurticaria of any duration as diagnosed by physicians. Patients were recruited from Asthma and Allergy Centers in Baghdad and Tikrit. The selected patients were divided randomly into 3 groups according to the treatment protocol. All patients completed screening before treatment. : The study indicated that cholinergicurticaria was completely controlled in 30.4